Conditions

Call for guidelines for prediabetes from the Clinical Endocrinologists meeting….

Severe insulin resistance, seen only through more extreme measurements, was identified in adolescent girls with and obesity…. 

This year at AACE, two studies were presented demonstrating liraglutide’s potential benefits in new patient populations. According to the studies, liraglutide appears to work both as an add-on to insulin in type 1 diabetes and as a weight-loss agent in nondiabetic patients.

Women with high levels of the liver enzyme gamma-glutamyl transferase before pregnancy may be more likely to develop gestational diabetes than those with lower levels…. 

  This week we wrap up our series of Homerun Slides from Dr. Stanley Schwartz covering the current state of obesity and the medication therapies available. We delve further in to the possibilities of combining insulin with the new incretin therapies including GLP-1’s and DPP-IV’s….

Richard S. Beaser, MD This week’s excerpt cover the following topics: Why a patient should start with multiple medications How much treatment is needed When to use combination therapy

An advanced framework for a new diagnostic approach to obesity was announced last week by the American Association of Clinical Endocrinologists (AACE) at their 23rd Scientific and Clinical Congress…. 

Exposure to diabetes in utero may significantly impair beta-cell function in children…. 

Researchers identified increases in three miRNAs and decreases in seven miRNAs in patients with type 2 diabetes…. 

Our publisher, Steve Freed, had a chance to talk with Dr. Stanley Schwartz, asking questions and getting some in-depth and very informative answers on exactly how SGLT-2 Inhibitors work.  Steve Freed: Regarding the SGLT2 drugs that are now available, I know that a lot of physicians just refuse to write …